Alison Moore
Director/Board Member bij CODEXIS, INC.
Vermogen: 3 M $ op 31-03-2024
Profiel
Momenteel bekleedt Alison Moore de functie van Chief Technical Officer bij Allogene Therapeutics, Inc. Dr. Moore zit ook in de raad van bestuur van Codexis, Inc. In het verleden bekleedde Dr. Moore de positie van Senior Vice President-Process Development bij Amgen, Inc. en Director-Chemistry, Manufacturing & Controls bij Genentech, Inc. Alison Moore behaalde een doctoraat en een undergraduate aan de Universiteit van Manchester.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
22-03-2023 | 670 173 ( 0.40% ) | 3 M $ | 31-03-2024 | |
CODEXIS, INC.
0.10% | 13-06-2023 | 68 576 ( 0.10% ) | 239 330 $ | 31-03-2024 |
Actieve functies van Alison Moore
Bedrijven | Functie | Begin |
---|---|---|
CODEXIS, INC. | Director/Board Member | 16-06-2020 |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Director/Board Member | - |
Eerdere bekende functies van Alison Moore
Bedrijven | Functie | Einde |
---|---|---|
ALLOGENE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 28-04-2023 |
AMGEN INC. | Corporate Officer/Principal | 01-06-2018 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | General Counsel | 01-01-2006 |
Opleiding van Alison Moore
The University of Manchester | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
AMGEN INC. | Health Technology |
CODEXIS, INC. | Process Industries |
ALLOGENE THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |